Gilead Scraps HR-MDS Trial; FDA OKs Verrica's Molluscum Treatment
- July 22nd, 2023
- 382 views
Gilead Sciences, Inc. (Nasdaq: GILD) announced the termination of the Phase 3 ENHANCE study evaluating magrolimab plus azacitidine as a first-line treatment for higher-risk myelodysplastic syndromes (HR-MDS) due to futility based on a planned analysis.
The safety data observed in this study aligns with the established magrolimab profile and the usual adverse events found in this patient population, prompting Gilead's recommendation to discontinue magrolimab treatment for MDS patients.
On Friday, $GILD closed at $80.64, reflecting a gain of $0.70 (+0.88%)
In other news, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) gained U.S. FDA approval for YCANTH (cantharidin) topical solution to treat molluscum contagiosum (molluscum) in adult and pediatric patients aged 2 years and older.
Molluscum is a highly contagious viral skin infection, mainly affecting children. YCANTH, a drug-device combination product, is expected to be available through healthcare professionals by September 2023.
$VRCA closed at $7.45 on Friday, up $0.28 (+3.83%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026
Member Login